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Summary We have carried out presymptomatic prediction of mutant gene carrier status in ten individuals
with a family history of retinoblastoma. In all cases standard linkage studies were employed using intragenic
DNA probes which recognise restriction fragment length polymorphisms. In four cases foetal DNA samples
were obtained by chorionic villus sampling, the remaining six were derived from either cord blood samples or
venipuncture of neonates. We demonstrated that the mutant gene was inherited by only one of these patients
who has subsequently developed bilateral tumours. Six of the other cases have now reached the age beyond
which it might have been expected that tumours would develop and are all disease free. It must be concluded
that repeated ophthalmological examination of these and future patients shown not to have inherited the
mutant gene, is unnecessary.
The application of 'reverse genetics' procedures has led to the
successful isolation of genes responsible for human genetic
disease in recent years. It is now commonplace, in the UK at
least, for these genes to be used in prenatal screening pro-
grammes to determine mutant gene carrier status in families.
The advantage of using the causative gene is that the chances
of recombination between marker and phenotype are very
small. However, despite the relative success in the isolation of
genes responsible for biochemical disorders such as PKU,
thalassemia, and many other genetic diseases there have been
few genes isolated and characterised which are responsible
for hereditary predisposition to cancer. The first, and still
most extensively -studied, cancer predisposition gene to be
isolated was the retinoblastoma gene, RB1 (Friend et al.,
1986).
Retinoblastoma (Rb) is an intraocular tumour of children
which has both hereditary and sporadic forms (Vogel, 1979;
Cowell, 1991). Only 15% of patients have a positive family
history although all bilateral cases (around 40%) are gener-
ally considered to be germ line carriers of a predisposing
mutation (Knudson, 1971). The Rb phenotype segregates as
an autosomal dominant trait with high penetrance (Vogel,
1979). The mean age of onset in hereditary cases is approxi-
mately 14 months (Draper, G.J., pers. comm.) compared
with 25-30 months for sporadic cases. Hereditary Rb rarely
arises after the age of two (although some cases present in
advanced forms in older children) and hardly ever after the
age of five. In patients with bilateral, multifocal disease their
tumours may develop sequentially over a period of months.
Treatment of small tumours has become very successful in
the past two decades with an overall survival of 90%. Early
detection of tumours, therefore, is the most critical feature in
the clinical management of the disease.
With the cloning of the RBl gene it was expected that the
cDNA probe could be used in standard linkage analysis to
identify restriction fragment length polymorphisms (RFLP).
This was not the case, however, and it was necessary to
isolate intragenic, unique-sequence DNA probes which recog-
nise RFLPs (Wiggs et al., 1988). These probes form the basis
of linkage studies in the analysis of Rb families worldwide
and have been successfully applied in 80-90% of families
(Wiggs et al., 1988; Scheffer et al., 1989; Onadim et al.,
1990). More recently other RFLPs and DNA sequence poly-
morphisms (Yandell & Dryja, 1989; McGee et al., 1989) have
been added to the armoury of probes available. In cases of
familial Rb, it is now possible to establish with which
chromosome the mutant allele segregates using standard link-
age studies (Cowell & Onadim, 1990). This, in turn, allows
for the unequivocal identification of gene carriers as well as
excluding those individuals who do not carry the mutant
gene. This analysis is particularly important in families where
incomplete penetrance occurs. There have been few reports,
however, of the successful application of the DNA probes in
prenatal and perinatal screening programmes for Rb. Since
the first ever report of prenatal prediction by Mitchell et al.
(1988) we have undertaken several additional tests in Rb
families and have been able to follow them for several years.
In this report we present our experience with presymptomatic
prediction using standard RFLP analysis and using DNA
obtained from foetal chorionic villus sampling and cord and
peripheral blood samples from neonates.
Materials and methods
Our Unit at the Institute of Child Health offers an extensive
service for family linkage studies and prenatal screening for
families from throughout the UK. This programme also
includes investigations of esterase-D (ESD) levels in affected
patients to detect individuals with 13q14 deletions (Cowell et
al., 1986; 1989). Although the majority of Rb patients in the
UK are referred to the Ophthalmology Departments at
Moorfields Eye Hospital and St Bartholomew's Hospital,
several families have been referred to us directly from other
regions in the UK.
All of the procedures for the RFLP analysis using the
probes RS2.0, PRO.6 (Wiggs et al., 1988) and M1.8 (Book-
stein et al., 1988) were as described previously (Onadim et
al., 1990). The procedures for PCR based detection of poly-
morphic sites have been described in Onadim and Cowell
(1991).
The RB1.20 polymorphism consists of a variable number
of {CTTT(T))} (n = 14-26) repeats (Yandell & Dryja, 1989)
and occurs 54 bp from the 3' end of exon 20.
The two primers used to amplify the RB1.20 polymorph-
ism were:
5' Primer 5'-GTATGAACTCATGAGACAGGCAT-3'
3' Primer 5'-AATTAACAAGGTGTGGTGGTACACG-3'
We tested a series of primers to amplify this region and
found this particular pair to give the best results. These are
not the same primers originally used by Yandell and Dryja
(1989).
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The 5' primer is from within exon 20 and the 3' primer
from intron 20 of the human RB gene. In a PCR reaction
they amplify a genomic DNA fragment (300-350 bp long
depending on the number of repeats) containing the RB1.20
VNTR region. PCR was carried out in a total volume of
50 LI containing; approximately 1 tLg DNA, 50 pmol of each
primer, 5Ail of 10 x Taq-polymerase buffer (Northumbria
Biologicals Limited), 0.2 mM each of dATP, dTTP, dGTP
and 0.02 mM dCTP, 1 tLCi 32P-dCTP and 1-2 units Taq
DNA polymerase (NBL). The NBL 10 x buffer consisted of
100mM Tris-HCI pH 8.8, 500mM KCI, 15 mM MgC2, 1%
Triton X-100. The reaction mix was overlaid with 501l of
mineral oil to prevent evaporation. Amplification was per-
formed using a programmable thermal cycle machine (Techne
PHC-1). Following an initial 15 min denaturation step at
96°C, after which the Taq polymerase enzyme was added,
amplification conditions consisted of three steps: denatura-
tion at 94°C for 20 s, annealing at 59°C for 20s, followed by
an extension step at 72°C for 60s. On completion of 30
cycles, the mineral oil was removed by chloroform extraction.
The individual PCR products were resolved by electrophor-
esis at constant power of 60 watts on 6% polyacrylamide
wedge gels containing 7 M urea for 6 h. Since allele sizes in
this polymorphism can differ by 1 bp, it is important not to
use a sample with too much radioactivity otherwise, follow-
ing autoradiography, bands of similar size tend to merge. We
therefore diluted the amplification product in serial dilutions
to find the optimum concentration, which was usually 1:10.
In the majority of cases, therefore, 1 itl of the PCR product
was diluted tenfold in amplification dilution solution (0.1%
SDS, 10 mM EDTA) and 1-2ftl of this dilution was mixed
with 2ftl of formamide dye mix (95% formamide, 20 ml
EDTA, 0.05% Bromophenol blue and 0.05% Xylene cyanol).
This solution was heated to 95°C for 5 min for denaturation
before loading into the gel. The gel was transferred onto 3 M
Whatmann filter paper and dried for 2 h. Dried gels were
overlaid with Kodak XAR-5 autoradiographic film and auto-
exposed at -70°C for 16-24 h with Cronex Quanta III
intensifying screens.
Results
For our genetic linkage analysis in Rb families we have used
RFLPs identified by probes RS2.0, PRO.6 and M1.8 which
are revealed following DNA digestion using Rsal, Xbal and
BamHI respectively (Wigg et al., 1988; Bookstein et al.,
1988). The Ml.8 probe recognises two variant alleles, the first
is 4.5 kb long and the second consists of a doublet 2.3 kb +
2.2 kb. For simplicity heterozygous individuals are described
throughout as 4.5/2.3 (instead of 4.5/2.3 + 2.2) (Figure 1).
Homozygous individuals for the lower allele are described as
2.3/2.3 (instead of 2.3 + 2.2/2.3 + 2.2). The conventional way
of identifying RFLPs using PRO.6 and Ml.8 is by Southern
blotting (Onadim et al., 1990). However, the same poly-
morphisms can also be detected using PCR techniques
(McGee et al., 1990; Bookstein et al., 1990; Onadim &
Cowell, 1991) where the allele sizes depend on the specific
oligonucleotides used. In PCR analysis it is the presence or
absence of the appropriate restriction enzyme site which
defines the polymorphism. In our study, which method was
used depended on the availability of DNA. When adequate
DNA was available both Southern blotting and PCR were
used for verification of the result. When DNA was limited,
PCR only was used. The allele sizes, as defined by Southern
blotting only, are given for each family. The polymorphic
VNTR, described as RB1.20, consists of many alleles which
can differ by as little as 1bp. It is difficult, therefore, to
estimate allele sizes between autoradiographs. For this reason,
we have numbered the alleles in each family separately,
labelling the alleles sequentially by size, the largest allele
being '1' and so on.
Using the RB1.20 VNTR 94% of individuals were report-
ed to be heterozygous (informative) at this locus (Yandell &
Dryja, 1989). In order to assess the relative informativity of
RB1.20 in the UK population we analysed 28 families from
our series. Approximately 80% of families were informative.
Among 55 unrelated individuals, 65% were heterozygous at
the RB1.20 locus. These figures are lower than those reported
by Yandell and Dryja (1989) but only 28 families were
studied and these do not represent a random sample since
they were chosen because they were uninformative using the
majority of the other intragenic DNA probes.
The pedigrees from all of the families for whom presymp-
tomatic screening was undertaken is given in Figure 1. In
Table I, the result of each presymptomatic screening carried
out was given for each family, together with the age at
testing, current age and the informative probes used. Screen-
ing followed the conventional protocol of examination, under
anaesthesia, of the retinae of both eyes every 3 months to the
age of 2, 4 months to the age of 3 and 6 months to the age of
5. In all, four prenatal and six post-natal tests were carried
out. Of these, only one was found to have inherited the
mutant RB1 gene (Figure 2). The first ever prenatal predic-
tion within an RB family (RBF 14) was reported by Mitchell
et al. in early 1988 where the chorionic villus sample was
taken afer 9 weeks of the pregnancy. For completeness, this
family pedigree is included with those studied here. Patient
III.2 who was shown not to carry the Rb predisposition allele
at the time of screening (Mitchell et al., 1988), is now 37
months old and, following repeated ophthalmological
examination, shows no evidence of a tumour. Families
RBF06, RBF13 and RBF14 were part of the series reported
by Onadim et al. (1990) which established the linkage rela-
tionship between intragenic probes and the Rb phenotype in
the UK. Family RBF29 represented an exceptional case
because of the unusual counselling given and the details of
the core family prior to the prenatal test have been reported
separately by Onadim et al. (1991). Our current report of
prenatal screening extends our analysis of these families.
In family RBF06 (Figure 1) post-natal screening of II.2
after 16 months and prenatal screening of II.3 showed that
neither inherited the mutant Rb gene, co-segregating with the
1.65 kb, RS2.0 allele from the affected father. This result was
confirmed using the M1.8 probe. Both II.2 and II.3 were
homozygous for the 2.3 kb allele whereas the RB predisposi-
tion clearly segregates with the 4.5 kb allele in this family.
In our experience families are usually only informative for
a few of the RFLPs. Clearly, the more probes that can be
used the more confident our predictions will be. In RBF06
we were able to confirm the results with a third polymorph-
ism, the RBl.20 VNTR. In this analysis, Rb predisposition
segregates with allele 5 in the family and, although no DNA
was available from 11.2, II.3 was not shown to inherit this
allele.
In family RBF13 (Figure 1) a post natal screen of II.2 was
undertaken when the child was 6 months old (reported in
Onadim et al., 1991) and, subsequently, a second post-natal
screen was performed after 0.5 months for II.3. Neither child
inherited the allele associated with Rb predisposition (1.95 kb
with RS2.0 and allele 2 with RB1.20).
Family RBF29 (Figure 1) has an unusual inheritance pat-
tern which was described by Onadim et al. (1991) where the
possibility of future prenatal screening was indicated. In
March 1991 we analysed a CV sample from the fetus (III.5)
who was found not to carry the Rb predisposition allele
(1.9 kb RS2.0; allele 6 RB1.20). Later, the predisposing
mutation itself was identified in this family. All the affected
individuals and unaffected gene carriers were found to carry
this mutation. The mutation was not present in III.5 (Ona-
dim et al., submitted).
In family RBF22 (Figure 1), the Rb mutation is segregat-
ing with the 1.95 kb allele identified by RS2.0 and the 6.5 kb
allele identified by PRO.6. III.2 who was already 10 months
old was excluded from carrying the mutant allele using both
probes. More recently (August, 1991) a second, post-natal
screen was .carried out in this family for III.3. This patient
was found to be heterozygous for PRO.6 which means that,
since both parents were also heterozygous at this locus, this
probe was not informative in his case. Using RS2.0, however,RETINOBLASTOMA SCREENING 713
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Figure 1 The pedigrees of the families for whom presymptomatic screening was undertaken. For each individual the size or the
number of alleles(s) for each informative polymorphism are given. An arrow / indicates the individuals for whom a presumpto-
matic prediction was given.
Table I The results offour prenatal and six post-natal screenings carried out in a period of4 years
(1988-1991) involving seven different families
Age at testing Age (11:91)
Family Proband (months) (months) Informativeprobes Predisposition Phenotype
RBF06 11.2 16 55 RS2.0, Ml.8 N Unaffected
RBF06 11.3 Prenatal 14 RS2.0, M1.8, RBI.20 N Unaffected
RBF13 11.2 6 40 RS2.0, RB1.20 N Unaffected
RBF13 11.3 0.5 19 RS2.0, RBI.20 N Unaffected
RBF14 111.2 Prenatal 37 RS2.0 N Unaffected
RBF29 111.5 Prenatal 01 RS2.0, RB1.20 N Unaffected
RBF32 111.2 10 34 RS2.0, PRO.6 N Unaffected
RBF32 111.3 4 9 RS2.0 N Unaffected
RBF33 III.1 0.25 3.5 RB1.20 Y Affected
RBF34 III.2 Prenatal - RS2.0, RBI.20 N Unaffected
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Figure 2 Linkage analysis in family RBF33 using the RB1.20
polymorphism. The VNTR region was amplified by using two
flanking primers in a reaction containing 32P dCTP. The products
were then separated on a denaturing polyacrylamide gel (see
Methods). III. was shown to have inherited the mutant RB
predisposition gene segregating with allele 3 in this family.
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III.3 was found not to have inherited the 1.95 allele and
therefore is expected to be unaffected.
Family RBF33 (Figure 1) was not informative for three of
the probes used in our screening programme, i.e. RS2.0,
PR0.6 and M1.8. They were, however, informative for the
polymorphism RB1.20. Using DNA from a cord blood
sample, III.1 was shown to have inherited the mutant Rb
predisposition gene segregating with allele 3 (Figure 2) in this
family. Two weeks later, ophthalmological examination of
III.1 identified tumours in both eyes.
Family RBF34 (Figure 1) was referred to us for assessment
for future prenatal screening having an affected child already.
Unusually this family was informative for all the polymor-
phic restriction enzyme sites analysed (Figure 3). Using the
RS2.0 probe the affected father was apparently homozygous
for the 1.75 kb allele (Figure 3b) which was unusual in that
his father II.1 did not carry this allele. His mother was not
available for analysis. At first, we considered non-paternity
as an explanation until patient 111.1 was shown apparently
not to have inherited an allele from his father also (Figure
3b). The same pattern of inheritence was shown for the
RB1.20 locus (Figure 3a). 11.1 was heterozygous however for
BamHI (Figure 3c) and XbaI (Figure 3d) polymorphisms. It
was clear that the predisposing mutation, which originated in
1.1, is a deletion including a part of intron 17 (after the XbaI
site) and extending at least to intron 20.
In August 1991 prenatal screening was carried out for II.2
after 11 weeks of pregnancy. The foetus was shown to inherit
the normal allele (allele 2) with RB1.20 and all of the other
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Figure 3 Linkage analysis in family RBF34, the pedigree for which is shown in the centre. Note 11.I and 111.1 have only a single
allele derived from their unaffected parents for the RBI.20 VNTR and the RS2.0 polymorphism shown in a and b respectively.
PCR analysis of polymorphisms revealed by the Ml.8 probe c and PRO.6 probe d confirm that the foetus 111.2 has not inherited the
mutant allele. M = marker lane containing the 1 kb DNA ladder (Gibco-BRL).
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probes from the affected father I.1 (Figure 3) and it is
therefore expected to be unaffected.
Discussion
We have followed a cohort of patients, with a family history
of Rb, who have received pre-symptomatic genetic screening.
In those cases where prenatal tests were performed, DNA
from chorionic villi were used and were obtained after
approximately 10 weeks of pregnancy. Post-natal tests are
carried out using DNA obtained from either cord blood or
whole blood obtained early in the child's life. Sometimes it is
difficult to obtain large volumes of blood from newborns.
This is not the case with cord blood samples. In cases where
families are informative for RB1.20, PRO.6 or M1.8, lack of
DNA is not a problem, since these polymorphisms can be
identified using PCR within 24 h. However, one of the
important probes used in Rb screening, RS2.0, still requires
reasonable amounts of DNA (5-10tg) and the results are
only available after 4-7 days.
Prior to our application of intragenic DNA probes to
prenatal screening in Rb families the only other such report
was by Cavenee et al. (1986). In this study markers flanking
the RB1 gene were used and met with limited success due to
recombination events between marker and Rb locus. Prenatal
screening was performed in five Rb families and the likeli-
hood of Rb was predicted in two cases and freedom from
disease in three. Two of the cases showed evidence of meiotic
recombination and the predictive accuracy in one other was
only 70% since only loci distal to the Rb locus were informa-
tive. We have previously been able to predict, pre-sympto-
matically, the development of Rb in two patients (J.C.,
unpublished data) who were carriers of chromosome 13 dele-
tions and who were identified using esterase-D measurements
in the series described by Cowell et al. (1989). In both cases
the referral for testing was warranted because of the presence
of other congenital abnormalities and dysmorphology which
are frequently associated with 13q14 deletions. Both patients
eventually developed Rb, before 12 months, although it
should be noted that not all such cases develop tumours
(Cowell et al., 1988; Wilson et al., 1987).
Our current series represents the first reported cases of
presymptomatic predictions which have been followed for
sufficient time to be sure that the prediction was accurate.
The majority of familial cases present before 2 years and we
have followed four patients for at least this period although,
since in fact, the mean age of onset is 14 months six have
reached this age disease free. A surprising result was that, to
date, all but one of the patients were shown not to have
inherited the mutant RB1 gene. There is still a small possi-
bility, however, that intragenic recombination might have
occurred. The RB1 gene consists of 27 exons spanning
approximately 200 kb of genomic DNA (Friend et al., 1987;
McGee et al., 1989). Assuming the generally accepted recom-
bination frequency of 1 cross-over per 106 base pairs, the
theoretical chances of recombination occurring within the
RB1 gene is 0.2, or 1:500. To date there have been no cases
of recombination in any of the families reported so far
(Wiggs et al., 1988; Scheffer et al., 1989; Onadim et al., 1990)
which surveyed approximately 140 meioses. The M1.8 unique
sequence DNA probe is located in the first exon of RB1
(Bookstein et al., 1988) and a VNTR locus occurring in the
3' intron adjacent to exon 20 (McGee et al., 1989) which
covers most of the gene (75%). If mutations can occur
equally along the length of the gene, as appears to be the
case at present (Yandell et al., 1989; Dunn et al., 1989), the
possibility of a predictive error is decreased accordingly if
patients are informative at these loci. Given this low chance
of intragenic recombination it must be concluded that it is
unnecessary to repeatedly screen patients shown not to have
inherited the predisposing mutation following linkage ana-
lysis.
In one of the families we described, RBF29, the predispos-
ing mutation itself was identified and III.5 was found not to
carry this mutation proving our prediction using polymor-
phic probes. Identification of the actual mutations require the
use of different techniques. Only gross structural rearrange-
ments and large deletions are detected by Southern blot
analysis. The majority of Rb mutations, however, are small
deletions or point mutations which require the use of techni-
ques such as SSCP (single strand conformation polymorph-
ism) and PCR sequencing. Using a combination of these
techniques, it is now theoretically possible to identify predis-
posing mutations in most Rb families and indeed to search
for predisposing mutations in constitutional DNA of sporadic
patients to determine whether or not they carry a germ-line
mutation. However, this approach is very expensive and time
consuming and, at present, it is not practical to analyse every
patient with Rb, although this situation might improve in the
future with the availability of quicker techniques and auto-
mated sequencing.
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